Oral azole antifungal prophylaxis in Japanese patients with chronic lymphocytic leukemia receiving ibrutinib: a nationwide cohort study.

There was no difference in the number of cases with >=3 prior treatment regimens between the azole prophylaxis and control groups, suggesting that antifungal prophylaxis is not a confounding variable for such treatment regimens. Ibrutinib, a first-generation inhibitor of Bruton's tyrosine kinase, is an important treatment option in chronic lymphocytic leukemia (CLL) [[1]]. For both the prophylaxis and control groups, data on ibrutinib treatment duration, prior CLL treatment regimens, oral azole prophylaxis, and corticosteroid treatments were collected at all relevant times during ibrutinib treatment. [Extracted from the article]